2020年1月14日
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Blood Advances
- 巻
- 4
- 号
- 1
- 開始ページ
- 66
- 終了ページ
- 75
- 記述言語
- 英語
- 掲載種別
- 研究論文（学術雑誌）
- DOI
- 10.1182/bloodadvances.2019000709
- 出版者・発行元
- American Society of Hematology
<title>Key Points</title>
KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.
KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.
- リンク情報
- ID情報
-
- DOI : 10.1182/bloodadvances.2019000709
- ISSN : 2473-9529
- eISSN : 2473-9537
- PubMed ID : 31899799
- PubMed Central 記事ID : PMC6960455